Role of bacillus Calmette-Guérin in the treatment of advanced melanoma (Q37952235)

25 August 2017

title

Role of bacillus Calmette-Guérin in the treatment of advanced melanoma (English)

1 reference

25 August 2017

John H Stewart

1

1 reference

25 August 2017

Edward A Levine

series ordinal

2

1 reference

25 August 2017

publication date

1 November 2011

1 reference

Expert Review of Anticancer Therapy

25 August 2017

published in

1 reference

25 August 2017

volume

11

1 reference

25 August 2017

issue

11

1 reference

25 August 2017

page(s)

1671-1676

1 reference

25 August 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

The effect of Bacille Calmette-Guérin on the evolution of new enhancing lesions to hypointense T1 lesions in relapsing remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Fact and fiction in tuberculosis vaccine research: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Bacillus calmette-guerin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Impact of vaccinations and infectious diseases on the risk of melanoma--evaluation of an EORTC case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Easter

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

An evidence-based staging system for cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

The stem-cell niche as an entity of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

The inflammatory tumor microenvironment and its impact on cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

High FOXP3+ regulatory T-cell density in the sentinel lymph node is associated with downstream non-sentinel lymph-node metastasis in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Effect of melanoma on immune function in the regional lymph node basin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Role of surgical intervention in the management of intestinal metastases from malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

Cytoreductive surgery for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.11.163

21 January 2018

Identifiers

DOI

10.1586/ERA.11.163

1 reference

25 August 2017

1 reference